There is insufficient evidence that oseltamivir reduces complications, hospitalizations and/or death in individuals suspected of having influenza. In addition, there is insufficient evidence of any benefit in individuals with suspected influenza who are at risk for developing complications. Evidence from one trial suggests that otherwise healthy individuals suspected of having influenza, return to normal activity faster when treated with oseltamivir than those receiving placebo. No studies are available to compare the magnitude of this benefit to amantadine, zanamivir or symptom-relieving medications.